2-[Fluorine-18]-fluoro-2-deoxy-d-glucose Positron Emission Tomography in the Diagnosis of Recurrent Ovarian Cancer
Authors:
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 83 (2) , 310-315
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical historyClinical Imaging, 1998
- Ovarian cancerPostgraduate Medicine, 1997
- Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancerInternational Journal of Gynecology & Obstetrics, 1996
- PET and [18F]-FDG in oncology: A clinical updateNuclear Medicine and Biology, 1996
- The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: A preliminary reportCancer, 1996
- Noninvasive Monitoring of Ovarian Cancer: Improved Results Using CT with Intraperitoneal Contrast Combined with ImmunocytologyGynecologic Oncology, 1994
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993
- 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomographyCancer, 1991